Intravenous recombinant tissue plasminogen activator (r-tPA) was approved for use in acute ischemic stroke in the United States in 1996. Approximately 2% to 5% of patients with acute ischemic stroke receive r-tPA. Complications related to intravenous r-tPA include symptomatic intracranial hemorrhage, major systemic hemorrhage, and angioedema in approximately 6%, 2%, and 5% of patients, respectively. Risk factors for symptomatic hemorrhage include age, male gender, obesity, increased stroke severity, diabetes, hyperglycemia, uncontrolled hypertension, combination antiplatelet use, large areas of early ischemic change, atrial fibrillation, congestive heart failure, and leukoariosis. A risk factor for angioedema is the use of angiotensin-converting enzyme inhibitor. Risk assessment scores, novel imaging strategies, and telemedicine may offer methods of optimizing the risk–benefit ratio.
BarberPAZhangJDemchukAMHillMDBuchanAM.Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology. 2001;56(8):1015–1020.
2.
DengYZReevesMJJacobsBS. IV tissue plasminogen activator use in acute stroke: experience from a statewide registry. Neurology. 2006;66(3):306–312.
3.
Del ZoppoGJSaverJLJauchECAdamsHPJr.Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. Stroke. 2009;40(8):2945–2948.
4.
KaseCSFurlanAJWechslerLR. Cerebral hemorrhage after intra-arterial thrombolysis for ischemic stroke: the PROACT II trial. Neurology. 2001;57(9):1603–1610.
5.
KhatriPHillMDPaleschYY. Methodology of the Interventional Management of Stroke III Trial. Int J Stroke. 2008;3(2):130–137.
6.
SmithWSSungGSaverJ. Mechanical thrombectomy for acute ischemic stroke: final results of the Multi MERCI trial. Stroke. 2008;39(4):1205–1212.
7.
Penumbra pivotal stroke trial investigators. The penumbra pivotal stroke trial: safety and effectiveness of a new generation of mechanical devices for clot removal in intracranial large vessel occlusive disease. Stroke. 2009;40(8):2761–2768.
8.
SaverJL.Hemorrhage after thrombolytic therapy for stroke: the clinically relevant number needed to harm. Stroke. 2007;38(8):2279–2283.
9.
Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group. Stroke. Nov1997;28(11):2109–2118.
10.
HackeWKasteMBluhmkiE. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359(13):1317–1329.
11.
GrahamGD.Tissue plasminogen activator for acute ischemic stroke in clinical practice: a meta-analysis of safety data. Stroke. 2003;34(12):2847–2850.
12.
MazighiMSerfatyJMLabreucheJ. Comparison of intravenous alteplase with a combined intravenous-endovascular approach in patients with stroke and confirmed arterial occlusion (RECANALISE study): a prospective cohort study. Lancet Neurol. 2009;8(9):802–809.
13.
BrownDLBarsanWGLisabethLDGalleryMEMorgensternLB.Survey of emergency physicians about recombinant tissue plasminogen activator for acute ischemic stroke. Ann Emerg Med. 2005;46(1):56–60.
14.
LongstrethWTJrKatzRTirschwellDLCushmanMPsatyBM.Intravenous tissue plasminogen activator and stroke in the elderly. Am J Emerg Med. 2010;28(3):359–363.
15.
TanneDKasnerSEDemchukAM. Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the Multicenter rt-PA Stroke Survey. Circulation. 2002;105(14):1679–1685.
16.
BerrouschotJRotherJGlahnJKucinskiTFiehlerJThomallaG.Outcome and severe hemorrhagic complications of intravenous thrombolysis with tissue plasminogen activator in very old (> or =80 years) stroke patients. Stroke. 2005;36(11):2421–2425.
17.
BluhmkiEChamorroADavalosA. Stroke treatment with alteplase given 3.0-4.5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial. Lancet Neurol. 2009;8(12):1095–1102.
18.
WahlgrenNAhmedNErikssonN. Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials: Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy (SITS-MOST). Stroke. 2008;39(12):3316–3322.
19.
CucchiaraBKasnerSETanneD. Factors associated with intracerebral hemorrhage after thrombolytic therapy for ischemic stroke: pooled analysis of placebo data from the Stroke-Acute Ischemic NXY Treatment (SAINT) I and SAINT II Trials. Stroke. 2009;40(9):3067–3072.
20.
ChernyshevOYMartin-SchildSAlbrightKC. Safety of tPA in stroke mimics and neuroimaging-negative cerebral ischemia. Neurology. 2010;74(17):1340–1345.
21.
DemchukAMMorgensternLBKriegerDW. Serum glucose level and diabetes predict tissue plasminogen activator-related intracerebral hemorrhage in acute ischemic stroke. Stroke. 1999;30(1):34–39.
22.
LansbergMGAlbersGWWijmanCA.Symptomatic intracerebral hemorrhage following thrombolytic therapy for acute ischemic stroke: a review of the risk factors. Cerebrovasc Dis. 2007;24(1):1–10.
23.
Rodriguez-GarciaJLBotiaEde La SierraAVillanuevaMAGonzalez-SpinolaJ.Significance of elevated blood pressure and its management on the short-term outcome of patients with acute ischemic stroke. Am J Hypertens. 2005;18(3):379–384.
24.
Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. Dec141995;333(24):1581–1587.
25.
TsivgoulisGFreyJLFlasterMPre-tissue plasminogen activator blood pressure levels and risk of symptomatic intracerebral hemorrhage. Stroke. Nov2009;40(11):3631–3634.
26.
DerexLHermierMAdeleinePClinical and imaging predictors of intracerebral haemorrhage in stroke patients treated with intravenous tissue plasminogen activator. J Neurol Neurosurg Psychiatry. Jan2005;76(1):70–75.
27.
DoradoLMillanMde la OssaNPInfluence of antiplatelet pre-treatment on the risk of intracranial haemorrhage in acute ischaemic stroke after intravenous thrombolysis. Eur J Neurol. Feb;17(2):301–306.
28.
DowlatshahiDHakimAFangJSharmaM. Pre admission antithrombotics are associated with improved outcomes following ischaemic stroke: a cohort from the Registry of the Canadian Stroke Network. Int J Stroke. Oct2009;4(5):328–334.
29.
HermannADzialowskiIKochRGahnG. Combined anti-platelet therapy with aspirin and clopidogrel: risk factor for thrombolysis-related intracerebral hemorrhage in acute ischemic stroke?J Neurol Sci. Sep152009;284(1-2):155–157.
30.
PatelSCLevineSRTilleyBCLack of clinical significance of early ischemic changes on computed tomography in acute stroke. JAMA. Dec122001;286(22):2830–2838.
31.
DemchukAMHillMDBarberPASilverBPatelSCLevineSR. Importance of early ischemic computed tomography changes using ASPECTS in NINDS rtPA Stroke Study. Stroke. Oct2005;36(10):2110–2115.
32.
MarlerJRTilleyBCLuMEarly stroke treatment associated with better outcome: the NINDS rt-PA stroke study. Neurology. Dec122000;55(11):1649–1655.
33.
ClarkWMAlbersGWMaddenKPHamiltonS. The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g) : results of a double-blind, placebo-controlled, multicenter study. Thromblytic therapy in acute ischemic stroke study investigators. Stroke. Apr2000;31(4):811–816.
34.
ZinkstokSNederkoornPVergouwenM. Safety of Thrombolysis in Patients with Acute Ischemic Stroke Caused by Cervical Artery Dissection-A Review. European Neurological Journal. 2010;2(1):65–72.
35.
AriesMJUyttenboogaartMVroomenPCDe KeyserJ, Luijckx GJ. tPA treatment for acute ischaemic stroke in patients with leukoaraiosis. Eur J Neurol. Jun1;17(6):866–870.
36.
PalumboVBoulangerJMHillMDInzitariDBuchanAM. Leukoaraiosis and intracerebral hemorrhage after thrombolysis in acute stroke. Neurology. Mar272007;68(13):1020–1024.
37.
DemchukAMKhanFHillMDImportance of leukoaraiosis on CT for tissue plasminogen activator decision making: evaluation of the NINDS rt-PA Stroke Study. Cerebrovasc Dis. 2008;26(2):120–125.
38.
BroderickJConnollySFeldmannEGuidelines for the management of spontaneous intracerebral hemorrhage in adults: 2007 update: a guideline from the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group. Stroke. Jun2007;38(6):2001–2023.
39.
MorgensternLBHemphillJC3rdAndersonCGuidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. Sep;41(9):2108–2129.
40.
AlbersGWBatesVEClarkWMBellRVerroPHamiltonSA. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA. Mar12000;283(9):1145–1150.
41.
Lopez-YunezAMBrunoAWilliamsLSYilmazEZurruCBillerJ. Protocol violations in community-based rTPA stroke treatment are associated with symptomatic intracerebral hemorrhage. Stroke. Jan2001;32(1):12–16.
42.
AdamsHPJr.del ZoppoGAlbertsMJGuidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke. May2007;38(5):1655–1711.
43.
AleuAMelladoPLichyCKohrmannMSchellingerPD. Hemorrhagic complications after off-label thrombolysis for ischemic stroke. Stroke. Feb2007;38(2):417–422.
44.
KimJTParkMSYoonWChoKH. Detection and Significance of Incidental Unruptured Cerebral Aneurysms in Patients Undergoing Intravenous Thrombolysis for Acute Ischemic Stroke. J Neuroimaging. Dec9.
45.
ScottPAFrederiksenSMKalbfleischJDSafety of intravenous thrombolytic use in four emergency departments without acute stroke teams. Acad Emerg Med. Oct;17(10):1062–1071.
46.
De SmedtADe RaedtSNieboerKDe KeyserJBrounsR. Intravenous thrombolysis with recombinant tissue plasminogen activator in a stroke patient treated with dabigatran. Cerebrovasc Dis. 2010;30(5):533–534.
47.
GadhiaJStarkmanSOvbiageleBAliLLiebeskindDSaverJL. Assessment and improvement of figures to visually convey benefit and risk of stroke thrombolysis. Stroke. Feb;41(2):300–306.
48.
LouMSafdarAMehdirattaMThe HAT Score: a simple grading scale for predicting hemorrhage after thrombolysis. Neurology. Oct282008;71(18):1417–1423.
49.
KentDMSelkerHPRuthazerRBluhmkiEHackeW. The stroke-thrombolytic predictive instrument: a predictive instrument for intravenous thrombolysis in acute ischemic stroke. Stroke. Dec2006;37(12):2957–2962.
50.
RudolfJGrondMSchmullingSNevelingMHeissW. Orolingual angioneurotic edema following therapy of acute ischemic stroke with alteplase. Neurology. Aug222000;55(4):599–600.
51.
HillMDLyeTMossHHemi-orolingual angioedema and ACE inhibition after alteplase treatment of stroke. Neurology. May132003;60(9):1525–1527.
52.
KidwellCSSaverJLMattielloJDiffusion-perfusion MRI characterization of post-recanalization hyperperfusion in humans. Neurology. 2001;57(11):2015–2021.
53.
SchwammLHHollowayRGAmarencoPA review of the evidence for the use of telemedicine within stroke systems of care: a scientific statement from the American Heart Association/American Stroke Association. Stroke. Jul2009;40(7):2616–2634.
54.
MeyerBCRamanRHemmenTEfficacy of site-independent telemedicine in the STRokE DOC trial: a randomised, blinded, prospective study. Lancet Neurol. Sep2008;7(9):787–795.
55.
SchellingerPDBryanRNCaplanLREvidence-based guideline: The role of diffusion and perfusion MRI for the diagnosis of acute ischemic stroke: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2010;75(2):177–185.
56.
TanJCDillonWPLiuSAdlerFSmithWSWintermarkM. Systematic comparison of perfusion-CT and CT-angiography in acute stroke patients. Ann Neurol. Jun2007;61(6):533–543.
57.
DavisSDonnanGParsonsMEffects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Lancet neurology. 2008;7(4):299–309.
58.
AlbersGThijsVWechslerLMagnetic resonance imaging profiles predict clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study. Annals of neurology. 2006;60(5):508–517.
59.
HackeWAlbersGAl-RawiYThe Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke. Jan2005;36(1):66–73.
60.
FurlanAJEydingDAlbersGWDose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke. May2006;37(5):1227–1231.
61.
HackeWFurlanAJAl-RawiYIntravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol. Feb2009;8(2):141–150.
62.
BarretoADMartin-SchildSHalleviHThrombolytic therapy for patients who wake-up with stroke. Stroke. Mar2009;40(3):827–832.
63.
KangD-WSohnS-IYuK-HReperfusion Therapy in Acute Ischemic Stroke with Unclear Onset by MRI Evaluation (RESTORE). Stroke. 2011;42(3):e110.
